WHO Drug Information Vol. 25, No. 2, 2011
WHO Drug Information Vol. 25, No. 2, 2011
WHO Drug Information Vol. 25, No. 2, 2011
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Proposed INN: List 105 <strong>WHO</strong> <strong>Drug</strong> <strong>Information</strong> <strong>Vol</strong>. <strong>25</strong>, <strong>No</strong>. 2, <strong>2011</strong>ixekizumabinmunoglobulina G4-kappa, anti-[Homo sapiens IL17A (interleukina17A, IL-17A)], anticuerpo monoclonal humanizado;cadena pesada gamma4 (1-445) [VH humanizada (Homo sapiensIGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homosapiens IGHG4*01 bisagra S10>P (227), CH3 K130>del (120-445)],(133-219')-disulfuro con la cadena ligera kappa (1'-219')[V-KAPPA humanizada (Homo sapiens IGKV2D-29*02 (89.00%) -IGKJ2*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')];dímero (2<strong>25</strong>-2<strong>25</strong>":228-228")-bisdisulfuroinmunomodulador1143503-69-8Heavy chain / Chaîne lourde / Cadena pesadaQVQLVQSGAE VKKPGSSVKV SCKASGYSFT DYHIHWVRQA PGQGLEWMGV 50INPMYGTTDY NQRFKGRVTI TADESTSTAY MELSSLRSED TAVYYCARYD 100YFTGTGVYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTKTY 200TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF LFPPKPKDTL <strong>25</strong>0MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL SLSLG 445Light chain / Chaîne légère / Cadena ligeraDIVMTQTPLS LSVTPGQPAS ISCRSSRSLV HSRGNTYLHW YLQKPGQSPQ 50LLIYKVSNRF IGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQSTHLP 100FTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200VTHQGLSSPV TKSFNRGEC 219Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-96 146-202 260-320 366-42422''-96'' 146''-202'' 260''-320'' 366''-424''Intra-L 23'-93' 139'-199'23'''-93''' 139'''-199'''Inter-H-L 133-219' 133''-219'''Inter-H-H 2<strong>25</strong>-2<strong>25</strong>'' 228-228''N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación296, 296''ladarixinumladarixinladarixineladarixina4-[(2R)-1-oxo-1-(methanesulfonamido)propan-2-yl]phenyltrifluoromethanesulfonateinterleukin 8 inhibitortrifluorométhanesulfonate de 4-[(2R)-1-oxo-1-(méthanesulfonamido)propan-2-yl]phényleinhibiteur de l'interleukine 8trifluoromethanesulfonato de 4-[(2R)-1-oxo-1-(metanosulfonamido)propan-2-il]fenilinhibidor de la interleukina 8C 11 H 12 F 3 NO 6 S 2 849776-05-2O OSF 3 C OHCH 3HN CH 3 SOOO176
Change language